Capital Allocation in an Era of Higher-for-Longer Rates
With central banks signalling prolonged elevated rates, the case for quality over growth strengthens. Where should patient capital be deployed?
Saman Capital operates with a singular mandate: to compound the capital entrusted to us at superior rates over the long term — through rigorous proprietary research, a selective process, and the patience to let our theses play out.
As a boutique firm, we are unconstrained by benchmarks, unencumbered by bureaucracy, and fully aligned with our clients. Every decision reflects our best independent thinking — not a committee's lowest common denominator.
Concentrated, high-conviction portfolios in listed equities across developed and emerging markets, emphasising quality businesses at reasonable valuations.
Selective participation in private equity and venture opportunities where our network and analytical edge provide access beyond public-market reach.
Tactical allocation to sovereign, corporate and structured credit instruments, focused on risk-adjusted yield and capital preservation.
Exposure to real estate and infrastructure that offers inflation protection, predictable cash flows, and genuine portfolio diversification.
No proprietary products to push, no distribution agreements, no corporate mandates that compete with our clients’ interests.
The firm’s principals hold meaningful personal capital in the same strategies we offer clients. Our interests are structurally aligned.
You speak directly with the portfolio managers and senior leadership who make investment decisions — never a relationship manager.
We manage assets at a scale where our strategies stay effective, and will close to new capital before size compromises our edge.
For qualified clients, we construct tailored mandates reflecting your objectives, constraints, tax circumstances, and existing portfolio.
Clear, honest performance reporting with full attribution — including an honest accounting of what went wrong, not only what went right.
With central banks signalling prolonged elevated rates, the case for quality over growth strengthens. Where should patient capital be deployed?
Broad diversification obscures a truth: exceptional long-term returns are built through deep knowledge of a small number of exceptional businesses.
Structural inefficiencies in emerging private markets still offer return premiums unavailable in liquid public markets. Our framework for finding them.